Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pepinemab - Vaccinex

Drug Profile

Pepinemab - Vaccinex

Alternative Names: Anti-SEMA4D monoclonal antibody - Vaccinex; moAb VX15/2503; VX 15; VX 15/2503

Latest Information Update: 20 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaccinex
  • Developer Bristol-Myers Squibb; Children's Oncology Group; Emory University; Merck KGaA; National Cancer Institute (USA); Teva Pharmaceutical Industries; UCLAs Jonsson Comprehensive Cancer Center; Vaccinex
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD100 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Phase I/II Non-small cell lung cancer; Osteosarcoma; Solid tumours
  • Phase I Colorectal cancer; Head and neck cancer; Malignant melanoma; Pancreatic cancer
  • No development reported Multiple sclerosis

Most Recent Events

  • 07 Dec 2018 Vaccinex plans a phase I trial for Malignant melanoma (Resectable, Combination therapy) in USA , (NCT03769155)
  • 12 Nov 2018 Safety data from cohort A of the phase II SIGNAL trial in Huntington’s disease released by Vaccinex
  • 01 Nov 2018 Phase-I clinical trials in Head and neck cancer (Combination therapy, First-line therapy) in USA (IV) (NCT03690986)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top